CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.08
−3.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 49.0K | — | 600.0K | — | 1.5M |
| Gross Profit | (49.0K) | — | (600.0K) | — | (1.5M) |
| Operating Expenses | |||||
| R&D Expense | 90.3M | 70.1M | 32.2M | 31.2M | 16.1M |
| SG&A Expense | 16.6M | 15.2M | 16.5M | 13.9M | 18.7M |
| General & Admin Expense | 16.6M | 15.2M | 16.5M | 13.9M | 18.7M |
| Selling & Marketing Expense | (49.0K) | — | — | — | — |
| Other Expenses | — | — | (600.0K) | — | (1.5M) |
| Total Operating Expenses | 106.8M | 85.3M | 48.1M | 45.1M | 33.3M |
| Cost and Expenses | 106.9M | 85.3M | 48.7M | 45.1M | 34.8M |
| Operating Income (EBIT) | (106.9M) | (85.3M) | (48.7M) | (45.1M) | (34.8M) |
| Non-Operating | |||||
| Interest Income | 3.9M | 5.5M | 6.3M | — | — |
| Interest Expense | — | — | 1.9M | 2.9M | 2.1M |
| Net Interest Income | 3.9M | 5.5M | 4.4M | (2.9M) | (2.1M) |
| Other Non-Op Income/Expense | 5.0M | 6.8M | 8.5M | 474.0K | (7.5M) |
| Non-Operating Income (excl Interest) | (5.0M) | (6.8M) | (10.4M) | (4.3M) | 5.4M |
| EBT (Pre-Tax Income) | (101.9M) | (78.5M) | (40.2M) | (44.6M) | (42.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (101.9M) | (78.5M) | (40.2M) | (44.6M) | (55.8M) |
| Earnings from Cont. Ops | (101.9M) | (78.5M) | (40.2M) | (44.6M) | (42.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (101.9M) | (78.5M) | (40.2M) | (44.6M) | (42.3M) |
| Per Share | |||||
| Basic EPS | ($6.48) | ($5.90) | ($3.68) | ($10.31) | ($10.15) |
| Diluted EPS | ($6.48) | ($5.90) | ($3.68) | ($10.31) | ($10.15) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 19.4M | 13.3M | 10.9M | 4.3M | 4.2M |
| Diluted Shares Outstanding | 19.4M | 13.3M | 10.9M | 4.3M | 4.2M |
| Profitability Metrics | |||||
| EBITDA | (101.1M) | (78.3M) | (37.7M) | (40.1M) | (38.7M) |
| D&A | 820.0K | 233.0K | 600.0K | 641.0K | 1.5M |
| EBIT | (101.9M) | (78.5M) | (38.3M) | (40.7M) | (40.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026